Pacific Edge Limited (PEB) is a global leader in cancer diagnostics, focusing on the development and commercialisation of bladder cancer diagnostic and prognostic tests. The company specialises in offering its suite of Cxbladder tests, which are crucial for patients presenting with hematuria or undergoing surveillance for recurrent disease. Headquartered in Dunedin, New Zealand, Pacific Edge operates wholly owned, CLIA-certified laboratories in New Zealand and the USA, ensuring global access to their advanced diagnostic solutions for bladder cancer.